Soriatane© (Acitretin) - A - Detailing from Skin Therapy Letter


Soriatane© (Acitretin)








  • Approved by the FDA for use in psoriasis in 1997
  • Used in monotherapy to treat generalized pustular, localized pustular and erythrodermic psoriasis
  • More effective at treating severe plaque-type psoriasis when used in combination with other treatments

Off-Label Uses

  • Darierís disease
  • Ichthyosiform erythroderma
  • Lamellar ichthyosis
  • Erythrokeratoderma variabilis
  • Lichen planus
  • Sjogren-Larsson Syndrome
  • Pityriasis rubra pilaris
  • Palmoplantar pustulosis
  • Post-transplantation: to reduce squamous cell carcinomas

Click here for more information on Off-Label Uses

Next:   Patient Profile